Taffic (Bictegravir/Emtricitabine/Tenofovir Alafenamide) 50mg/200mg/25mg*30's | Generic HIV-1 | GLT

Generic Information: Taffic (India)

Taffic is the Indian generic version of Gilead's Biktarvy, manufactured by Hetero Drugs, one of the world's largest producers of antiretroviral medicines. It was the first generic bictegravir/emtricitabine/tenofovir alafenamide combination launched in India, receiving DCGI approval and entering the market in December 2019. Each once-daily tablet contains bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg, mirroring the originator's composition exactly.

What Is Taffic Used For?

Taffic is used to treat HIV-1 infection in adults who are starting antiretroviral therapy for the first time, or to replace a current regimen in people who have been virologically suppressed (fewer than 50 copies per mL) for at least three months with no prior treatment failure or resistance. It is a complete single-tablet regimen, meaning patients take just this one pill a day rather than a multi-tablet combination, which supports long-term adherence.

How Does Taffic (BIC/FTC/TAF) Work?

Taffic works through the same two mechanisms as the originator. Bictegravir, an integrase strand transfer inhibitor, stops HIV from inserting its genetic material into human DNA, while emtricitabine and tenofovir alafenamide, both nucleoside reverse transcriptase inhibitors, block the virus from copying its RNA into DNA. Together they drive viral load down to undetectable levels and prevent the virus from multiplying.

Indications

Taffic is indicated for HIV-1 infection in treatment-naive adults and as a switch for virologically suppressed patients on a stable regimen. It is produced under a voluntary licence from Gilead through the Medicines Patent Pool, which authorizes Hetero to manufacture and distribute the combination in designated low- and middle-income countries. Hetero announced availability in 116 such countries subject to local regulatory approval.

Dosage

The dose is one tablet once daily, with or without food, and the tablet should be swallowed whole. As with the originator, Taffic is not recommended for patients with severely reduced kidney function (creatinine clearance below 30 mL per minute), and hepatitis B status should be checked before starting because of the risk of hepatitis flare on stopping treatment. Patients should follow their specialist's viral-load monitoring schedule after any switch.

Side Effects

The most common side effects are diarrhea, nausea, and headache, matching the documented profile of the bictegravir/emtricitabine/tenofovir alafenamide combination. Bictegravir can cause a mild rise in serum creatinine without harming true kidney function, and total bilirubin may increase. The same boxed warning applies: stopping the medicine in someone coinfected with hepatitis B can trigger a severe hepatitis flare, so monitoring is required.

Storage

Store Taffic at room temperature in a dry place, in its original packaging, and away from children. No cold storage is needed, which makes it practical for home use and for shipping to warmer climates.

Why Choose the India Generic Taffic?

For patients paying out of pocket, Taffic offers a major cost advantage over the branded originator. Because Hetero manufactures under a Medicines Patent Pool voluntary licence and is a long-standing WHO-prequalified supplier of antiretrovirals, the price reflects manufacturing cost plus royalty rather than patent-protected brand pricing — without sacrificing the cGMP manufacturing standards. This makes years of daily HIV therapy financially sustainable for patients in lower-income settings.

How to Order

To order Taffic through GLT, contact us on WhatsApp at +86 15234153837 or email [email protected]. Provide the strength, quantity, and your destination country, and we will confirm availability, sourcing, and the shipping terms for your region. We work with both institutional buyers and individual patients.

FAQ

Is Taffic the same as Biktarvy? Taffic is the Indian generic of Biktarvy, containing the identical three active ingredients at the same doses — bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg.

Who makes Taffic? Taffic is manufactured by Hetero Drugs of Hyderabad, India, and was the first generic bictegravir combination launched in India in December 2019.

Is Taffic licensed? Yes. It is produced under a voluntary licence from Gilead through the Medicines Patent Pool and is approved by India's DCGI.